GLP-1 analogs: a comparison of new anti diabetic medications - presenting benefits and risks
DOI:
https://doi.org/10.12775/JEHS.2024.62.014Keywords
GLP-1 analogs, diabetes, obesity, pharmacologyAbstract
Introduction and purpose: Diabetes has emerged as a global lifestyle disease, with an alarming rise in cases, particularly of type 2 diabetes. In Poland, over 3 million people are diagnosed, and an estimated 4 million cases are expected by 2030. Effective treatment involves a multifaceted approach, including dietary intervention, physical activity, and pharmacological options. Incretins, such as glucagon-like peptide-1 (GLP-1), play a pivotal role in carbohydrate metabolism regulation, and GLP-1 analogs have become essential in managing type 2 diabetes. This paper explores the development and mechanisms of GLP-1 analogs, detailing their impact on insulin secretion, gastric emptying, and weight reduction.
Description of the state knowledge: Various GLP-1 receptor agonists, including exenatide, liraglutide, dulaglutide, semaglutide, and the novel tirzepatide, are discussed. These drugs exhibit diverse pharmacokinetics, modes of administration, and effects on glucose metabolism and weight. Despite their efficacy, there is a concerning trend of off-label use, particularly for obesity treatment, leading to shortages for patients with valid prescriptions. This misuse is fueled by para-advertising on social media platforms, contributing to a surge in prescriptions and reimbursement costs. To address this, guidelines for GLP-1 analog use in obesity treatment are proposed, emphasizing the need for a stable drug supply and normalizing drug availability.
Summary: In 2023, concerns intensified with reports of counterfeit GLP-1 analogs, prompting regulatory interventions. The paper concludes by underscoring the critical role GLP-1 analogs play in diabetes and obesity treatment, while emphasizing the importance of responsible prescription practices, guidelines adherence, and regulatory vigilance to ensure patient safety and mitigate the risks associated with misuse and counterfeit drugs.
References
Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta,
GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2020.
Topor-Madry R, Wojtyniak B, Strojek K, et al. Prevalence of diabetes in Poland: a combined
analysis of national databases. Diabet Med. 2019;36(10):1209–216.
Towpik I, Walicka M, Marcinkowska K et al., Epidemiology of diabetes in Poland in 2014–2017.
Clin Diabetol 2020; 9, 5: 279–285.
NFZ o Zdrowiu. Centrala Narodowego Funduszu Zdrowia Departament Analiz i Strategii,
Warszawa, 2019:2-5.
Cloete L. Diabetes mellitus: an overview of the types, symptoms, complications and
management. Nurs Stand. 2022 Jan 5;37(1):61-66.
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type
Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020
Mar;10(1):107-111.
Tinajero MG, Malik VS. An Update on the Epidemiology of Type 2 Diabetes: A Global
Perspective. Endocrinol Metab Clin North Am. 2021 Sep;50(3):337-355.
Sieradzki J. (red.). Cukrzyca. T. 2. Wydawnictwo Via Medica. Gdańsk 2020: 7-21.
Fabian W., Zozulińska - Ziółkiewicz D., Zasady postępowania w cukrzycy - zalecenia dla lekarzy
POZ (aktualizacja 2019), Lekarz rodzinny, wydanie specjalne, 1/2019: 38-45.
Moczulskiego D. (red.). Diabetologia. Medical Tribune Polska. Warszawa 2023: 23-43.
Araszkiewicz A, Bandurska-Stankiewicz E, Borys S i in. Zalecenia kliniczne dotyczące
postępowania u osób z cukrzycą 2023.Curr Top Diabetes. 2023, 3, 1: 1-140.
Mastalerz-Migas A, Czupryniak L, Fabian W i in. Wytyczne rozpoznawania i leczenia cukrzycy
dla lekarzy rodzinnych Polskiego Towarzystwa Medycyny Rodzinnej, Kolegium Lekarzy
Rodzinnych w Polsce i Polskiego Towarzystwa Diabetologicznego. Lekarz POZ. 2022, 4: 232.
Franek E., Walicka M., Leczenie cukrzycy w praktyce klinicznej. Tom 1, Wydawnictwo
Lekarskie PZWL, Warszawa 2018, s. 23.
Ikegami H, Hiromine Y, Noso S. Insulin-dependent diabetes mellitus in older adults: Current
status and future prospects. Geriatr Gerontol Int. 2022 Aug;22(8):549-553.
Drucker DJ, Holst JJ. The expanding incretin universe: from basic biology to clinical
translation. Diabetologia. 2023 Oct;66(10):1765-1779.
Bhushan A, Butler AE i wsp. Sustained beta cell apoptosis in patients with long-standing type 1
diabetes: indirect evidence for islet regeneration? Diabetologia 2005; 48: 2221–2228.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2
diabetes - state-of-the-art. Mol Metab. 2021;46:101102.
Boer GA, Hay DL, Tups A. Obesity pharmacotherapy: incretin action in the central nervous
system. Trends Pharmacol Sci. 2023 Jan;44(1):50-63.
Nauck MA, Müller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023
Oct;66(10):1780-1795.
Holst JJ, Gasbjerg LS, Rosenkilde MM. The Role of Incretins on Insulin Function and Glucose
Homeostasis. Endocrinology. 2021 Jul 1;162(7):bqab065.
Holst JJ, Ørskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulinreleasing
hormone from the distal gut. FEBS Lett. 1987;211:169–174.
Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin
activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory
polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91(1):301–307.
Gasbjerg LS, Helsted MM, Hartmann B, et al. Separate and combined glucometabolic effects of
endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy
individuals. Diabetes. 2019;68:906–917.
Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and incretin-based therapies
on gastrointestinal motor function. Exp Diabetes Res. 2011;2011:279530.
Ramracheya RD, McCulloch LJ, Clark A, et al. PYY-dependent restoration of impaired insulin
and glucagon secretion in type 2 diabetes following Roux-en-Y gastric bypass surgery. Cell Rep.
;15:944–950.
Camastra S, Palumbo M, Santini F. Nutrients handling after bariatric surgery, the role of
gastrointestinal adaptation. Eat Weight Disord. 2022 Mar;27(2):449-461.
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2
diabetes - state-of-the-art. Mol Metab. 2021 Apr;46:101102.
American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches
to glycemic treatment: Standards of Medical Care in Diabetes—2022. Diabetes
Care . 2022;45:S125–SS43.
Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed
to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L
cells of the porcine intestine. Endocrinology. 1999 Nov;140(11):5356-63.
Li N, Lu J, Willars GB. Allosteric modulation of the activity of the glucagon-like peptide-1
(GLP-1):metabolite GLP-1 9-36 amide at the GLP-1 receptor. PloS one. 2012;7 (10):e47936.
Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1) receptor agonists and
neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacol Res. 2022
Dec;186:106550.
Yap MKK, Misuan N. Exendin-4 from Heloderma suspectum venom: From discovery to its
latest application as type II diabetes combatant. Basic Clin Pharmacol Toxicol. 2019
May;124(5):513-527.
Ratajczak A, Szulińska M, Bogdański P. Agoniści GLP-1 dla lekarzy praktyków. Forum
Zaburzeń Metabolicznych 2014, tom 5, nr 4, 165–171.
Müller TD, Finan B, Bloom SR, et al. Glucagon‐like peptide 1 (GLP‐1). Mol Metab 2019; 30:
–130.
Holst JJ. The incretin system in healthy humans: the role of GIP and GLP‐
Metabolism 2019; 96: 46–55.
Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes
Metab 2018; 20: 5–21.
Jakubowicz D, Wainstein J, Ahrén B, et al. Fasting until noon triggers increased postprandial
hyperglycemia and impaired insulin response after lunch and dinner in individuals with type 2
diabetes: a randomized clinical trial. Diabetes Care 2015; 38: 1820–1826.
Liss DT, Cherupally M, O'Brien MJ, Kang RH, Aikman C, Wallia A, Cooper AJ, Koep E,
Parker ED, Ackermann RT. Treatment modification after initiating second-line medication for type
diabetes. Am J Manag Care. 2023 Dec;29(12):661-668.
Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, Mather KJ, Karanikas CA, Dunn J,
Haupt A, Milicevic Z, Coskun T. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in
People With Type 2 Diabetes. Diabetes Care. 2023 May 1;46(5):998-1004.
Dotson CD, Vigues S, Steinle NI, Munger SD. T1R and T2R receptors: the modulation of
incretin hormones and potential targets for the treatment of type 2 diabetes mellitus. Curr Opin
Investig Drugs. 2010 Apr;11(4):447-54.
Tengholm A. Cyclic AMP dynamics in the pancreatic β-cell. Ups J Med Sci. 2012
Nov;117(4):355-69.
Pandey S, Mangmool S, Parichatikanond W. Multifaceted Roles of GLP-1 and Its Analogs: A
Review on Molecular Mechanisms with a Cardiotherapeutic Perspective. Pharmaceuticals (Basel).
Jun 3;16(6):836.
Anglart G, Janik L, Dettlaff K. Tirzepatyd – nowy analog hormonów inkretynowych. Farmacja
Polska. 2023, 79, 5: 289-296.
Salehi M, Aulinger B, Prigeon RL, D'Alessio DA. Effect of endogenous GLP-1 on insulin
secretion in type 2 diabetes. Diabetes. 2010 Jun;59(6):1330-7.
Andrews CN, Bharucha AE, Camilleri M, Low PA, Seide BM, Burton DD, Nickander KK,
Baxter KL, Zinsmeister AR. Effects of glucagon-like peptide-1 and sympathetic stimulation on
gastric accommodation in humans. Neurogastroenterol Motil. 2007 Sep;19(9):716-23.
Górska A, Arciszewski MB. Występowanie i funkcja peptydu glukagonopodobnego 1 (GLP-1)
w przewodzie pokarmowym ssaków oraz zastosowanie kliniczne jego analogów. Med. Weter. 2020,
, 7: 382-388.
Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas.
Pharmacol Ther. 2007 Mar;113(3):546-93.
Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, Drucker DJ. International Union
of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev. 2003;55:167–194.
Gasbjerg LS, Bergmann NC, Stensen S, Christensen MB, Rosenkilde MM, Holst JJ, Nauck M,
Knop FK. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists.
Peptides. 2020 Mar;125:170183.
Gilbert MP, Pratley RE. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy:
Review of Head-to-Head Clinical Trials. Front Endocrinol (Lausanne). 2020 Apr 3;11:178.
Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment.
Pharmacol Rev. 2008 Dec;60(4):470-512.
Kieć-Klimczak M. Doustne testy tolerancji lipidów i glukozy, a wydzielanie inkretyn (GLP-1 i
GIP) u pacjentów z zespołem metabolicznym o różnym genotypie TCF7L2. Rozprawa doktorska.
Kraków 2011: 33-35.
Płaczkowska S, Kokot I, Pawlik-Sobecka L, Piwowar A. Glucagon-like peptide-1 profile during
oral glucose tolerance test in young people. Clin Diabetol 2017; 6, 5: 151–158.
Cai Y, Wei L, Ma L, Huang X, Tao A, Liu Z, Yuan W. Long-acting preparations of exenatide.
Drug Des Devel Ther. 2013 Sep 5;7:963-70.
Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. N Engl J
Med. 2008;358(18):1969–1972.
Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, Nandula SA, Nawaz FK, Tracey K,
Yang H, LeRoith D, Brownstein MJ, Roth J. Glucagon-like peptide-1: a multi-faceted antiinflammatory
agent. Front Immunol. 2023 May 17;14:1148209.
Davies M., Pieber T.R., Hartoft-Nielsen M.L., Hansen O.K.H., Jabbour S., Rosenstock J. Effect
of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in
patients with type 2 diabetes: a randomized clinical trial. Journal of the American Medical
Association. 2017;318:1460–1470.
Muscogiuri G, Gastaldelli A. Albiglutide for the treatment of type 2 diabetes. Drugs Today
(Barc). 2014 Oct;50(10):665-78.
Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R, Rinaldi L, Marfella R, Sasso
FC. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future
Perspectives. Int J Mol Sci. 2023 J: 23-43.
Pan H, Xie Y, Lu W, Chen Y, Lu Z, Zhen J, Wang W, Shang A. Engineering an enhanced
thrombin-based GLP-1 analog with long-lasting glucose-lowering and efficient weight reduction.
RSC Adv. 2019 Sep 27;9(53):30707-30714.
Cirincione B, Mager DE. Population pharmacokinetics of exenatide. Br J Clin Pharmacol. 2017
Mar;83(3):517-526.
Michałowska J, Bogdański P. Rola hormonów i leków inkretynowych w terapii otyłości i
wybranych zaburzeń metabolicznych. Forum Zaburzeń Metabolicznych 2021;12(2):61-69.
Bhavsar S, Mudaliar S, Cherrington A. Evolution of exenatide as a diabetes therapeutic. Curr
Diabetes Rev. 2013 Mar 1;9(2):161-93.
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J,
Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N,
Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Effects of Once-Weekly
Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017 Sep
;377(13):1228-1239.
Ye ZR, Yan CQ, Liao N, Wen SH. The Effectiveness and Safety of Exenatide Versus Metformin
in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Reprod Sci. 2023 Aug;30(8):2349-2361.
Kim D., MacConell L., Zhuang D., Kothare P.A., Trautmann M., Fineman M. Effects of onceweekly
dosing of a long-acting release formulation of exenatide on glucose control and body weight
in subjects with type 2 diabetes. Diabetes Care. 2007;30:1487–1493.
Daniele G., Iozzo P., Molina-Carrion M., Lancaster J., Ciociaro D., Cersosimo E., et al.
Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis
and reward system. Diabetes. 2015;64(10):3406–3412.
Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022
Mar;57:101351.
Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural
circuitry. Am J Physiol Regul Integr Comp Physiol. 2016 May 15;310(10):R885-95.
Wilding JPH, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with
overweight or obesity. N Engl J Med 2021;384:989–1002.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda
(MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Lixisenatide. 2019
Apr 10.
Prescribing Information: Lyxumia (lixisenatide) solution for injection. MAT-XU-2204701
(V1.0). Sanofi. Reading, United Kingdom. 18.10.2022.
Ratner RE, Rosenstock J, Boka G, Investigators DRIS. Dose-dependent effects of the oncedaily
GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled
with metformin: a randomized, doubleblind, placebo-controlled trial. Diabet Med. 2010;27:1024–
Becker RH, Kapitza C, Stechl J, Ruus P, Msihid J. Restitution of glucose disposition with
lixisenatide in T2DM subjects. Diabetes. 2012;61:A212–A344. Abstract 1081-P.
Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. Efficacy and safety of the once-daily GLP-1
receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial
in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012;35:1225–31.
D.S. Shyangdan, P. Royle, C. Clar i wsp. Cochrane Database of Systematic Reviews, 2011; 10:
CD006423.
Raz I, Fonseca V, Kipnes M, Durrwell L, Hoekstra J, Boldrin M, Balena R. Efficacy and safety
of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment:
results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1). Diabetes
Care. 2012 Mar;35(3):485-7.
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child
Health and Human Development; 2006–. Dulaglutide. 2018 Dec 3. PMID: 30000038.
Frias JP, Bonora E, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, Malik R, Bethel MA, Cox DA.
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-
Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes
Care. 2021 Mar;44(3):765-773.
Muskiet MHA, Tonneijck L, Smits MM, et al. GLP-1 and the kidney: from physiology to
pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017; 13(10): 605–628.
Dhruv UA, Gupta OP. Glucagon like peptide 1 receptor agonists: glycaemic control and beyond.
JCD. 2016; 4(2): 18–25.
Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in
patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;
(9861): 117–124.
Umpierrez G., Tofé Povedano S., Pérez Manghi F. et al. Efficacy and safety of dulaglutide
monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
Diabetes Care 2014; 37: 2168–2176.
Alghamdi A, Alsaeddi A, Malki H, Alsaedi A. A Case Report of a Pregnant Woman With Type 2
Diabetes Mellitus Using Dulaglutide During the First Trimester of Pregnancy. Cureus. 2023 Sep
;15(9):e44644.
Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN. Semaglutide as a promising
antiobesity drug. Obes Rev. 2019 Jun;20(6):805-815.
Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021 Jul
;12:645563.
Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends
Cardiovasc Med. 2023 Apr;33(3):159-166.
Goldenberg RM, Steen O. Semaglutide: Review and Place in Therapy for Adults With Type 2
Diabetes. Can J Diabetes. 2019 Mar;43(2):136-145.
Roy Chaudhuri S, Majumder A, Mukherjee P, Sanyal D, Chakraborty S, Chuyan S. Glycemic
Control and the Weight Benefit of a Daily 7 mg Dose of Oral Semaglutide Versus an Alternate-Day
mg Dose of Oral Semaglutide From an Ambulatory Glucose Monitoring Data: A Retrospective
Cohort Study From Eastern India. Cureus. 2023 Jun 9;15(6):e40179.
Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human
GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Granhall
C, Donsmark M, Blicher TM, Golor G, Søndergaard FL, Thomsen M, Bækdal TA. Clin
Pharmacokinet. 2019;58:781–791.
Rybelsus. Charakterystyka produktu leczniczego. Novo Nordisk. Warszawa 2022: 1-15.
Wełnicki M, Gorczyca-Głowacka I, Mamcarz A, et al. The use of GLP-1 analogues in the
treatment of diabetes in patients with cardiovascular diseases. The expert opinion of the Working
Group of Cardiovascular Pharmacotherapy of the Polish Cardiac Society. Kardiol Pol. 2022;
(12): 1286–1298.
Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients
with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019; 42(12):
–2281.
Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021 Jul
;12:645563.
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I,
McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1
Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP
trial extension. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564.
Anglart G, Janik L, Dettlaff K. Tirzepatyd – nowy analog hormonów inkretynowych. Farmacja
Polska. 2023. 79, 5: 289-296.
Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to
titrated insulin glargine on glycemic control in patients with type 2 diabetes: The SURPASS-5
randomized clinical trial. JAMA 2022; 327(6): 534–545.
Stachyra B, Wolanin M, Stawikowski C i in. Tirzepatide - a novel dual GLP-1 and GIP receptor
agonist used in pharmacotherapy of obesity: A literature review. Journal of Education, Health
andSport. 2023;18(1):23-33.
Komunikat do fachowych pracowników ochrony zdrowia. Novo Disk Pharma. Warszawa
12.2023:1-2.
Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight
and obesity: A review. Diabetes Obes Metab. 2023 Jan;25(1):18-35.
BąkSosnowska M., Białkowska M., Bogdański P., Chomiuk T., GałązkaSobotka M., Holecki
M., Jarosińska A., Jezierska M., Kamiński P., Kłoda K., KręgielskaNarożna M., Lech M., Mamcarz
A., Mastalerz-Migas A., Matyjaszek-Matuszek B., Ostrowska L., Płaczkiewicz Jankowska E.,
Stachowska E., Stelmach Mardas M., Szeliga J., Szulińska M., Walczak M., Wyleżoł M.: Zalecenia
kliniczne dotyczące postępowania u chorych na otyłość 2022 – stanowisko Polskiego Towarzystwa
Leczenia Otyłości. Med. Prakt. wyd. specj.; maj 2022: 1–87.
Pasek, I., Wiska, L., Kopytko, P., & Banach, B. (2021). Leczenie otyłości u pacjentów z
cukrzycą typu 2. Farm Pol, 77(7), 442-450.
Brown E, Wilding JPH, Barber TM, Alam U, Cuth- bertson DJ. Weight loss variability with
SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic
possibilities. Obes Rev. 2019; 20(6): 816–828.
Orłowski, W., Merkisz, K., Zdun, S., Walczak, K., Walczak, P., Nemeczek, S., i inni. (2023).
GLP-1 agonists in treatment of obesity. Journal of Education, Health and Sport, 13(2), 229-234.
M. Miłkowski. Podsekretarz Stanu. Odpowiedź dla E. Witek, Marszałek Sejmu
Rzeczypospolitej Polskiej. PLD.050.26.2022.SG. Minister Zdrowia. 02.2022. Warszawa: 1-2.
Miłkowski M. Podsekretarz Stanu. Do M. Wiącek, Rzecznik Praw Obywatelskich.
PLD.054.41.2023.KW. Minister Zdrowia: 1-4.
Sienicka A, Kubasik K, Pisula A. The glukagon-like peptide-1 analogues therapy in the nondiabetic
patients. Prospects in Pharmaceutical Sciences. 2023. 21, 1: 9-14.
Sourris KC, Ding Y, Maxwell SS, Al-Sharea A, Kantharidis P, Mohan M, Rosado CJ, Penfold
SA, Haase C, Xu Y, Forbes JM, Crawford S, Ramm G, Harcourt BE, Jandeleit-Dahm K, Advani A,
Murphy AJ, Timmermann DB, Karihaloo A, Knudsen LB, El-Osta A, Drucker DJ, Cooper ME,
Coughlan MT. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney
disease through dampening the receptor for advanced glycation end products-induced inflammation.
Kidney Int. 2024 Jan;105(1):132-149.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Marika Dębik, Łukasz Szydłowski, Klaudia Żurowska, Artur Bednarski, Aleksandra Krużel, Seweryn Ziajor, Piotr Sajdak, Justyna Tomasik, Marcel Stodolak, Kamil Kłos
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 544
Number of citations: 0
